Abstract
Background: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe cutaneous adverse reaction (SCAR) that is a result of an immune-mediated cascade orchestrated by activated cytotoxic T-cells leading to the release of granulysin, perforin, and interferon-gamma. Despite its high morbidity and mortality, there is no established standard of care for the pharmacological management of SJS/TEN patients. The rationale behind use of etanercept, a TNF-alpha inhibitor, has been supported by case reports and small mechanistic studies, though the current literature is limited and dispersed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
